Focused On-demand Library for Polynucleotide 5'-hydroxyl-kinase NOL9

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q5SY16

UPID:

NOL9_HUMAN

Alternative names:

Nucleolar protein 9

Alternative UPACC:

Q5SY16; Q2NL84; Q4VBY3; Q6P472; Q7L4D6; Q96EE0; Q9H5L4

Background:

Polynucleotide 5'-hydroxyl-kinase NOL9, also known as Nucleolar protein 9, plays a pivotal role in rRNA processing. This enzyme's kinase activity is crucial for the transformation of the 32S precursor into 5.8S and 28S rRNAs, particularly generating the major 5.8S(S) form. Exhibiting both DNA and RNA 5'-kinase activities in vitro, NOL9 likely engages in RNA binding, underscoring its essential function in cellular biology.

Therapeutic significance:

Understanding the role of Polynucleotide 5'-hydroxyl-kinase NOL9 could open doors to potential therapeutic strategies. Its central function in rRNA processing suggests that modulation of its activity could influence protein synthesis, offering a novel approach to target diseases at the molecular level.